<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667927</url>
  </required_header>
  <id_info>
    <org_study_id>AMLREM</org_study_id>
    <nct_id>NCT00667927</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission</brief_title>
  <official_title>Autologous Bone Marrow Transplant for Children With AML in First Complete Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to transfer marker genes (detectable genetic traits or segments of DNA&#xD;
      that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow&#xD;
      Transplant (BTM) in patients in remission of Acute Myelogenous Leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study was to estimate the continuous complete remission rate at&#xD;
      2 years post transplant for children with AML in first complete remission treated with&#xD;
      autologous BMT.&#xD;
&#xD;
      Secondary objectives used transduction of marker genes into autologous marrow to determine&#xD;
      the following:&#xD;
&#xD;
        1. whether the source of relapse after BMT for AML is residual malignant cells in the&#xD;
           harvested marrow or in the patient, and whether marrow purging is therefore rational.&#xD;
&#xD;
        2. whether the majority of AML, which lack genetic markers, represent abnormalities in a&#xD;
           multi-lineage progenitor cell, and whether therefore, auto grafting/intensified&#xD;
           chemotherapy is ever likely to augment the cure rate.&#xD;
&#xD;
        3. the mechanisms of autologous reconstitution, and the effects of stimuli which modify the&#xD;
           process.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1991</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 1995</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the continuous complete remission rate at 2 years for children with AML in first complete remission treated with Autologous Bone Marrow Transplant (ABMT).</measure>
    <time_frame>2 years post transplant</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cytoxan, CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MESNCX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged between 1 and 18 years at diagnosis with acute nonlymphocytic leukemia&#xD;
             in first remission are eligible for this protocol.&#xD;
&#xD;
          -  Patients enrolled on the AML-87 study in second or subsequent remission are eligible&#xD;
             for this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has an HLA-matched, MLC-compatible donor(unless parents and/or patient refuses&#xD;
             transplant.&#xD;
&#xD;
          -  Diagnosis of FAB M3 or FAB M3v (acute progranulocytic leukemia)&#xD;
&#xD;
          -  Life expectancy limited by disease other than leukemia&#xD;
&#xD;
          -  Significant cardiac disease (echo shortening fraction &lt;25% or MUGA scan &lt;50%)&#xD;
&#xD;
          -  Severe renal dysfunction, i.e., creatinine clearance less than 60cc/1.73 m2/min&#xD;
&#xD;
          -  Severe restrictive pulmonary disease (FCV less than 40% of predicted)&#xD;
&#xD;
          -  Severe hepatic disease (bilirubin greater than 3 mg/dl or SGPT greater than 500IU)&#xD;
&#xD;
          -  Severe personality disorder or mental illness&#xD;
&#xD;
          -  Previous severe cystitis from cyclophosphamide&#xD;
&#xD;
          -  Previous total dose of anthracyclines of &gt;450 mg/m2&#xD;
&#xD;
          -  Sever infection that on evaluation by the PI precludes ablative chemotherapy or&#xD;
             successful transplantation&#xD;
&#xD;
          -  Previous autologous transplant&#xD;
&#xD;
          -  HIV reactivity&#xD;
&#xD;
          -  Karnofsky score &lt;70%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory A Hale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <last_update_submitted>April 25, 2008</last_update_submitted>
  <last_update_submitted_qc>April 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Hale, Gregory A</name_title>
    <organization>St. Jude Children's Research Hospital</organization>
  </responsible_party>
  <keyword>Autologous bone marrow transplant</keyword>
  <keyword>gene marking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

